Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

被引：1

作者：

Cohen, Yael C. ^{[1
,2
]}

Magen, Hila ^{[2
,3
]}

Lavi, Noa ^{[4
]}

Gatt, Moshe E. ^{[5
]}

Chubar, Evgeni ^{[6
]}

Kreiniz, Natalia ^{[7
]}

Tadmor, Tamar ^{[8
]}

Trestman, Svetlana ^{[9
]}

Vitkon, Roy ^{[10
]}

Rouvio, Ory ^{[11
]}

Shvetz, Olga ^{[12
]}

Shaulov, Adir ^{[13
]}

Avivi, Irit ^{[2
,14
]}

机构：

[1] Tel Aviv Sourasky Ichilov Med Ctr, Dept Hematol, Tel Aviv, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[3] Chaim Sheba Med Ctr, Ramat Gan, Israel

[4] Rambam Med Ctr, Haifa, Israel

[5] Hadassah Hebrew Univ, Med Ctr, Hematol Dept, Jerusalem, Israel

[6] HaEmek Med Ctr, Hematol Unit, Afula, Israel

[7] Bnai Zion Med Ctr, Hematol Unit, Haifa, Israel

[8] Technion, Ruth & Bruce Rappaport Fac Med, Bnai Zion Med Ctr, Hematol, Haifa, Israel

[9] Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel

[10] Tel Aviv Sourasky Med Ctr, Dept Haematol, Tel Aviv, Israel

[11] Soroka Med Ctr, Dept Hematol, Beer Sheva, Israel

[12] Hadassah & Hebrew Univ, Med Sch, Kaplan Med Ctr, Hematol, Rehovot, Israel

[13] Hadassah Hebrew Univ, Med Ctr, Dept Haematol, Jerusalem, Israel

[14] Tel Aviv Sourasky Med Ctr, Inst Hematol, Tel Aviv, Israel

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-114217

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1972

引用

页数：4

共 17 条

[1] Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
Cohen, Yael C.
Magen, Hila
Lavi, Noa
Gatt, Moshe E.
Chubar, Evgeni
Horowitz, Nethanel
Kreiniz, Natalia
Tadmor, Tamar
Trestman, Svetlana
Vitkon, Roy
Rouvio, Ory
Shvetz, Olga
Shaulov, Adir
Ziv-Baran, Tomer
Avivi, Irit
[J]. ANNALS OF HEMATOLOGY, 2020, 99 (06) : 1273 - 1281
[2] Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
Yael C. Cohen
Hila Magen
Noa Lavi
Moshe E. Gatt
Evgeni Chubar
Nethanel Horowitz
Natalia Kreiniz
Tamar Tadmor
Svetlana Trestman
Roy Vitkon
Ory Rouvio
Olga Shvetz
Adir Shaulov
Tomer Ziv-Baran
Irit Avivi
[J]. Annals of Hematology, 2020, 99 : 1273 - 1281
[3] Real World Data on the Efficacy and Safety of Ixazomib Based Therapy in Multiple Myeloma: An Observational Study from China
Li, Jing
Zhuang, Jingli
Wei, Zheng
Ji, Liji
Cheng, Zhixiang
Liu, Peng
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E265 - E265
[4] The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China
Li, Jing
Bao, Li
Xia, Zhong-jun
Ding, Kaiyang
Li, Bingzong
Chen, Bing
Fu, Zhengzheng
Wang, Sili
Zhang, Wenhao
Zhou, Xin
Hua, Luoming
Yang, Wei
Jun, Luo
Wang, Liang
Xu, Tianhong
Yang, Yang
Wang, Weida
Wu, Guolin
Huang, Yun
Liu, Peng
[J]. BLOOD, 2019, 134
[5] "Real World" Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed / Refractory Multiple Myeloma: A Combined Study from the Greek, Czech and UK Databases
Terpos, Evangelos
Maouche, Nadjoua
Minarik, Jiri
Katodritou, Eirini
Jenner, Matthew W.
Plonkova, Hana
Gavriatopoulou, Maria
Vallance, Grant
Pika, Tomas
Kotsopoulou, Maria
Kothari, Jaimal
Jelinek, Tomas
Kastritis, Eftathios
Aitchison, Robin
Dimopoulos, Meletios A.
Ramasamy, Karthik
Hajek, Roman
[J]. BLOOD, 2017, 130
[6] MACHINE LEARNING-BASED PREDICTION OF THE TIME TO NEXT TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS FROM REAL-WORLD-DATA
Azarias, G.
Merker, L.
Schilling, S.
Strobel, K.
Kellermann, L.
Wischlen, S.
[J]. VALUE IN HEALTH, 2022, 25 (07) : S577 - S577
[7] Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study
Charalampous, Charalampos
Kumar, Shaji Kunnathu
Parrondo, Ricardo
Chhabra, Saurabh
Duh, Mei Sheng
Bobbili, Priyanka
Wang, Aolin
Chen, Jingyi
Mohan, Manasi
Hlavacek, Patrick
Ren, Jinma
Schepart, Alex
Nador, Guido
DiBonaventura, Marco
[J]. BLOOD, 2023, 142
[8] Real-world outcomes of sequencing elotuzumab (elo)-based regimens following daratumumab (dara) in patients with relapsed/refractory multiple myeloma: results from the Connect® MM Registry
Ailawadhi, Sikander
Durie, Brian
Narang, Mohit
Omel, James
Wagner, Lynne
Toomey, Kathleen
Terebelo, Howard
Lee, Hans
Abonour, Rafat
Gasparetto, Cristina
Rifkin, Robert
Hardin, James
Lee, Kim
Dhanasiri, Sujith
Gentili, Christian
Yu, Edward
Jou, Ying-Ming
Jagannath, Sundar
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S161 - S161
[9] BORTEZOMIB-BASED THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-WORLD MEDICAL PRACTICE: FINAL DATA FROM THE INTERNATIONAL, OBSERVATIONAL EVOBS STUDY
Terpos, E.
Katodritou, E.
de la Rubia, J.
Hungria, V.
Hulin, C.
Roussou, M.
Delforge, M.
Bries, G.
Stoppa, A.
Aagesen, J.
Sargin, D.
Belch, A.
Diels, J.
Chirita, O.
Olie, R.
Robinson, D., Jr.
Dhawan, R.
Ganguly, R.
Potamianou, A.
van de Velde, H.
Dimopoulos, M.
[J]. HAEMATOLOGICA, 2013, 98 : 601 - 601
[10] Ixazomib plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (RRMM) patients in real-world experience: a pooled analysis from the INSIGHT MM observational study and the Czech Registry of Monoclonal Gammopathies (RMG)
Weisel, K.
Hajek, R.
Terpos, E.
Lee, H. C.
Chari, A.
Costello, C. L.
Puig, N.
Leleu, X.
Berdeja, J. G.
Davies, F. E.
Usmani, S. Z.
Hungria, V. T. M.
Boccadoro, M.
Rifkin, R. M.
Zonder, J. A.
Cook, G.
Brozova, L.
Barinova, M.
Ren, K.
Skacel, T.
Stull, D. M.
Maisnar, V.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 125 - 125

← 1 2 →